GlassScriptPhysician profile
Elizabeth C Ridley
NPI 1801036629
$11,060.87
in general payments reported to CMS, 2019-2025
28 companies · $2,166 in 2025
The $2,166 reported for 2025 was more than what 94% of Physician Assistant providers received nationally (typical 2025 total: $183).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $1,495 · 2022: $2,041 · 2023: $2,564 · 2024: $2,794 · 2025: $2,166.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $7,207 · Education: $318.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $7,206.92 |
| Education | $317.98 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $1,878.93 | 2021-2025 | |
| Novartis Pharmaceuticals Corporation | $1,050.30 | 2021-2025 | |
| Janssen Biotech, INC. | $964.12 | 2021-2025 | Tremfya, Simponi, Stelara |
| E.R. Squibb & Sons, L.L.C. | $911.34 | 2022-2025 | Sotyktu |
| Pfizer INC. | $855.65 | 2021-2025 | |
| Leo Pharma INC. | $845.19 | 2021-2025 | Adbry, Anzupgo |
| Amgen INC. | $742.73 | 2021-2025 | Otezla, Otezla |
| Sun Pharmaceutical Industries INC. | $715.58 | 2021-2025 | Ilumya, Winlevi |
| Incyte Corporation | $516.22 | 2022-2025 | Opzelura |
| Lilly USA, LLC | $368.96 | 2021-2025 | Taltz, Ebglyss, Olumiant |
| Ucb, INC. | $342.27 | 2021-2025 | Bimzelx, Cimzia |
| Dermavant Sciences, INC. | $330.17 | 2023-2024 | Vtama |
| Genzyme Corporation | $313.93 | 2022-2025 | |
| Organon LLC | $203.38 | 2025 | Vtama, Nexplanon |
| Galderma Laboratories, L.P. | $179.27 | 2021-2025 | Aklief, Nemluvio, Oracea |
Show all 28 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Regeneron Healthcare Solutions, INC. | $178.31 | 2021-2025 | Dupixent, Libtayo |
| Sanofi-Aventis U.S. LLC | $158.98 | 2022-2024 | |
| Mayne Pharma Commercial LLC | $149.03 | 2022-2024 | |
| Ortho Dermatologics, A Division of Bausch Health US, LLC | $92.64 | 2021-2025 | Cabtreo, Jublia, Arazlo |
| Biofrontera INC. | $52.10 | 2023-2025 | Ameluz, Xepi, Bf-Rhodoled |
| Journey Medical Corporation | $41.81 | 2022-2024 | |
| Almirall LLC | $34.67 | 2025 | Klisyri, Seysara |
| Epi Health, LLC | $32.65 | 2021-2022 | |
| Arcutis Biotherapeutics, INC. | $30.33 | 2024-2025 | Zoryve |
| Dermira, INC. | $19.76 | 2021 | |
| Sandoz INC. | $19.51 | 2021 | |
| Verrica Pharmaceuticals INC. | $16.54 | 2024 | Ycanth |
| Mission Pharmacal Company | $16.50 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Elizabeth Ridley listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.